Bevacizumab Products - Oncology
Customize your policy alerts
Sign up for blue cross blue shield - louisiana Policy MA-214 alerts
Get alerted when Policy MA-214 changes without checking for updates manually.
Monitor payer policy activity
This Medicare Advantage medical policy governs coverage and prior authorization for bevacizumab reference and biosimilar products used for oncology indications. Coverage depends on contract benefits, medical necessity, and, for non-preferred products, failure or expected ineffectiveness or adverse reaction to both preferred biosimilars unless an exception applies.
The preferred bevacizumab biosimilar was changed from Mvasi to Vegzelma.
The policy title and patient-selection note were revised to specify that the policy applies to oncology indications and not intravitreal use.
A Novitas Medicare Billing Article link was added for intravitreal bevacizumab use.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.